GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Amphiphilic Coatings Developed Using Plasma Copolymerization Show Antibacterial and Antifouling Properties

by GOAI
Share To

Researchers have developed amphiphilic coatings using plasma copolymerization of oxazoline and fluoro monomers, which demonstrate antibacterial and antifouling properties. The study outlines the synthesis process and evaluates the effectiveness of these coatings in preventing bacterial adhesion and biofilm formation, as well as their resistance to fouling by various contaminants.

The research team employed plasma polymerization techniques to create thin films composed of oxazoline and fluoro-based monomers. These coatings were tested for their ability to inhibit bacterial growth, specifically targeting common pathogens associated with infections and contamination. Additionally, the study assessed the antifouling capabilities of the coatings against organic pollutants and other fouling agents. Results indicated that the amphiphilic nature of the materials contributed to their dual functionality, combining hydrophilic and hydrophobic properties to effectively repel bacteria and contaminants. The findings suggest potential applications in medical devices, marine environments, and industrial settings where antibacterial and antifouling surfaces are required.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top